S784
Clinical - Lung
ESTRO 2026
peripheral, early-stage non-small cell lung cancer (ES- NSCLC). Material/Methods: ES-NSCLC patients with T1-T2N0 disease (with a small subsection of T3) treated with SABR at a single UK oncology centre between January 2016 and December 2019 were included. Treatment was guided by UK SABR Consortium criteria and IASLC staging version 7 and 8 with patients receiving either 54 Gy in 3 fractions, 55 Gy in 5 fractions or 60 Gy in 8 fractions. Data, including Charlson co-morbidity index, was collected from our electronic patient record and radiotherapy planning software. The following prognostic factors were assessed using uni and multi- variate analysis in a cox regression model: Gender, age at time of SABR, age, smoking status, T stage, tumour location, WHO performance status, deprivation, dose, IGTV, PTV, mean lung and heart dose, Charlson co- morbidity index (CCI), FEV1, FEV1/FVC and diffusion capacity of the lung for carbon monoxide (DLCO). Overall survival was estimated using the Kaplan-Meier method. Hazard ratios (HR) are reported with 95% confidence intervals (CI). Results: 474 consecutive ES-NSCLC patients treated with SABR were identified. The mean age was 74.8 years (IQR 70- 81), with 136 (28.7%) ≤ 70 and 338 (71.3%) >70 years old respectively. 45.4% (n=215) were male with 89.5% (n=424) having a smoking history. Median pretreatment DLCO was 52.61%, median FEV1 was 70% and median CCI was 9. Median overall survival was 41 months (CI 37-44) with 1-year, 3-year and 5- year overall survival being 88%, 54.9% and 32.5% respectively. Significant prognostic factors from the MVA for 5-year overall survival were age >70 years old (HR 1.53), WHO PS 2-3 vs PS 0-1 (HR 1.52), pretreatment DLCO ≤ 60% (HR 1.43) and IGTV >30 cm3 vs ≤ 10cm3 (HR 1.94).
45–60 Gy) in 15 fractions. Maintenance immunotherapy was administered in 79% (n=27) with a median of 12 cycles (range: 4–69). At a median follow-up of 17 months (range: 7–93), the 1- and 2-year LC rates were 94% and 88%. RR rates were 6% and 15%, and DM rates 18% and 29%. No isolated local or regional recurrence was observed. OS at 1, 2, and 5 years was 86%, 81%, and 62%; PFS was 76%, 54%, and 40%, respectively (Figure 1). Toxicity was acceptable: Grade 1–2 and grade 3 esophagitis occurred in 74% and 9%, with no grade 4–5 events. Radiation pneumonitis occurred in 9% and immunotherapy- related pneumonitis in 15%.
Conclusion: Consolidative hypofractionated RT following induction chemoimmunotherapy, along with maintenance immunotherapy, appears safe and efficacious in patients with locally advanced inoperable NSCLC, managed through a dedicated multidisciplinary tumor board. Favorable LC and survival outcomes were achieved with limited high-grade toxicity. Compared with the PACIFIC trial, our results provide encouraging evidence supporting this treatment approach. Keywords: Lung cancer, immunotherapy, definitive RT Digital Poster 2163 Prognostic factors and survival in early stage lung SABR; a single centre UK experience Will Barnsley 1 , Lynn Bell 2 , Helen Wong 3 , Michelle Forshaw 2 , Nicola Rankin 2 , Rebecca Cleator 2 , Andrew Corns 2 , Anoop Haridass 1 , David Cobben 4 1 Clinical oncology, Clatterbridge Cancer Centre, Liverpool, United Kingdom. 2 Radiotherapy, Clatterbridge Cancer Centre, Liverpool, United Kingdom. 3 Statistics, Clatterbridge Cancer Centre, Liverpool, United Kingdom. 4 Radiation oncology, Clatterbridge Cancer Centre, Liverpool, United Kingdom Purpose/Objective: To evaluate prognostic factors for survival in patients receiving stereotactic body radiotherapy (SABR) for
Made with FlippingBook - Share PDF online